COMPARISON OF 2 COMBINATION CHEMOTHERAPY REGIMENS FOR MULTIPLE-MYELOMA - METHYL-CCNU, CYCLOPHOSPHAMIDE, AND PREDNISONE VERSUS MELPHALAN AND PREDNISONE

Google Scholar
  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (1) , 73-79
Abstract
Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU [1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosurea], cyclophosphamide and prednisone (group A); 72 received melphalan and prednisone (group B). Respectively, 48 and 33% had good responses; the overall response rates (good plus partial) were 75 and 65% for groups A and B, respectively. The survival curves for both groups of patients were similar, with a median survival of 32 mo. At 36 mo., 70% of those patients who obtained good response were alive, 29% of those with partial response were alive, and 13% of those with no response were alive. The clinical staging system described by Durie and Salmon shows a good prognosis for stage I patients, with 80% remaining alive at 48 mo.; the survival curves for stage II and III patients were similar, with 33 and 28%, respectively, remaining alive at 48 mo. The combination of methyl-CCNU cyclophosphamide and prednisone is not more effective in terms of response rate or duration of survival than melphalan and prednisone.

This publication has 1 reference indexed in Scilit: